Myasthenia gravis with thymoma
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Progress in the pathogenesis, diagnosis, and treatment of thymomatous myasthenia gravis (MG) has been made in the past several decades. These advances have occurred along diverse lines of immunology, molecular genetics, and tumor cytopathology. The most widely used classification for thymoma closely correlates with tumor biology, prognosis, and the likelihood of association with MG. There is a sensitive immunoassay for the detection of striational autoantibodies, which are closely related to the presence of thymoma, although their precise origin is still debated. Chest computed tomography (CT) can delineate a thymoma with extraordinary accuracy and sensitivity. The goal of treatment is complete removal of the tumor and remission or sustained improvement of MG. This is usually achievable with trans-sternal maximal thymectomy and chronic immunosuppressant medication. In this article, we consider aspects of the historical background, pathogenesis, diagnosis, and treatment of thymomatous MG.
Historical background.
There was no mention of thymic abnormalities in the classic descriptions of myasthenia patients by Wilks, [1] Erb, [2] Goldflam, [3] and Jolly, [4] or among the autopsies reported by Campbell and Bramwell at the turn of the century [5] until 1901 when Laquer and Weigert [6,7] described a patient with myasthenia and a thymic tumor. Later, Bell, [8] Blalock, [9,10] and others found that the thymus gland in myasthenia was enlarged or the site of a tumor in the majority of patients at surgery or autopsy. Thymectomy, with the intention to resect the gland totally became standard treatment. [11-15]
The estimated overall frequeny of thymoma in MG varies from 15 to 30%. [16-22] It is more common with increasing age, with an estimated frequency of 3% for age 20 years or younger, 12% for ages 21 to 45, and 35% for age 46 years and older. [23] Although detection of thymoma most often follows the clinical diagnosis of MG, …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Five New Things
Myasthenia gravisFive new thingsJeffrey M. Statland, Emma Ciafaloni et al.Neurology: Clinical Practice, April 15, 2013 -
Review
Signs heralding appearance of thymomas after extended thymectomy for myasthenia gravisErnestina Santos, Ana Martins Silva, Philipp Stroebel et al.Neurology: Clinical Practice, November 07, 2018 -
Research Article
Impact of the Surgical Approach to Thymectomy Upon Complete Stable Remission Rates in Myasthenia GravisA Meta-analysisPaola Solis-Pazmino, Ioana Baiu, Eddy Lincango-Naranjo et al.Neurology, May 04, 2021 -
Articles
Association of acetylcholine receptor α-subunit gene expression in mixed thymoma with myasthenia gravisA. Wilisch, S. Gutsche, V. Hoffacker et al.Neurology, April 01, 1999